Tvardi Therapeutics (TVRD) FCF Margin (2013 - 2025)
Tvardi Therapeutics (TVRD) posted FCF Margin of 299.3% for Q1 2025, up 9.89% sequentially from 332.16% in Q4 2024, and up 116623.0% YoY from N/an in Q1 2024.
Tvardi Therapeutics (TVRD) FCF Margin (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported FCF Margin for 13 years, with the latest figure at 299.3% in Q1 2025.
- Quarterly FCF Margin rose 116623.0% year-over-year to 299.3% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 56.12% (up 58934.0% YoY) and the FY2024 annual result came in at 271.14%, up 17933.0% from the prior year.
- FCF Margin climbed to 299.3% in Q1 2025 per TVRD's latest filing, from 332.16% in the prior quarter.
- Over five years, FCF Margin peaked at 2467.51% in Q2 2024 and troughed at 1465.53% in Q1 2024.
- A 5-year average of 298.44% and a median of 316.36% in 2024 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 276240 bps in 2024, down 90400 bps in 2024.
- Over 5 years, FCF Margin stood at 151.64% in 2021, then sank by 375 bps to 720.94% in 2022, then advanced by 13 bps to 630.43% in 2023, then soared by 47 bps to 332.16% in 2024, then gained by 10 bps to 299.3% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 299.3%, 332.16%, and 300.55% for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -299.30% |
| Dec 31, 2024 | -332.16% |
| Sep 30, 2024 | -300.55% |
| Jun 30, 2024 | 2,467.51% |
| Mar 31, 2024 | -1,465.53% |
| Dec 31, 2023 | -630.43% |
| Sep 30, 2023 | -403.72% |
| Jun 30, 2023 | -294.89% |
| Mar 31, 2023 | -561.52% |
| Dec 31, 2022 | -720.94% |
| Sep 30, 2022 | -232.98% |
| Jun 30, 2022 | -19.58% |
| Mar 31, 2022 | -533.78% |
| Dec 31, 2021 | -151.64% |
| Sep 30, 2021 | -69.63% |
| Mar 31, 2021 | -1,225.89% |
| Dec 31, 2020 | 73.44% |
| Sep 30, 2020 | -233.33% |
| Jun 30, 2020 | -490.81% |
| Mar 31, 2020 | -473.29% |